Development of a UPLC-MS/MS method for the determination of lacosamide and its metabolite and its application to drug-drug interaction

Lacosamide, a third-generation novel antiepileptic drug, was first approved in 2008 as an adjunct to partial seizures. In 2014, the U.S. Food and Drug Administration (FDA) approved it as a single agent for partial seizures. Since epilepsy is a chronic condition, most patients need long-term antiepil...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jie, Shen, Yuxin, Xia, Hailun, Chen, Xiaohai, Xu, Ren-Ai, Lin, Guanyang, Dai, Gexin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667685/
https://www.ncbi.nlm.nih.gov/pubmed/38026954
http://dx.doi.org/10.3389/fphar.2023.1265252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667685/
https://www.ncbi.nlm.nih.gov/pubmed/38026954
http://dx.doi.org/10.3389/fphar.2023.1265252

Ejemplares similares